ASCO 2024 - Michael Petroutsas

Just two months into his new position as US president and head of commercial for Astellas, Michael Petroutsas joined pharmaphorum editor-in-chief Jonah Comstock for a conversation on the sidelines of ASCO 2024.
In the video below, Petroutsas discusses a few of Astellas’s 16 abstracts at the show, including sharing news about the company’s new November PDUFA date for zolbetuximab in gastric cancer.
But, in a wide-reaching conversation, Comstock and Petroutsas also discuss Astellas’s larger strategy of focusing on targeted therapies and ADCs for conditions with high unmet need and the importance of incorporating real-world evidence into drug development, including the implications for health equity.
And they talk about the increasing desire among researchers to bring new therapies into frontline settings more quickly and what will be required to facilitate that paradigm shift. Finally, Petroutsas lays out some of the ways he thinks AI is going to be most influential on drug development.
There’s something for everyone in this video from ASCO 24, so check it out.
Subscribe to the pharmaphorum RUclips channel for in-depth conversations with innovators across healthcare: / @pharmaphorum
Join us on Twitter for the latest news, features, event coverage, and discussions: / pharmaphorum
And for everything, everywhere, all at once, visit our official site: pharmaphorum.com/